New CEO Appointed - Nov 2003
David Darling
David Darling has been appointed Chief Executive Officer of Dunedin-based cancer genetics research company Pacific Edge Biotechnology Limited (PEBL). David joins PEBL from his role as Director of Business Development, Biotechnology, for Rubicon Ltd.
David joined Fletcher Challenge and entered the forest industry in 1982 after completing a degree in Agricultural Science at Massey University and a degree in Forestry Science from Canterbury University .
David has had considerable experience developing start-up companies and developing early stage technologies. He has been involved in the entrepreneurial development of nutraceuticals, herbal medicines, biotechnology, forestry, and horticulture. His roles in the building of biotech start-up companies have also involved the management of Intellectual Property platforms.
David was actively involved in the development and start-up of ArborGen, a biotechnology joint venture business between Rubicon and two North American forestry giants, International Paper and MeadWestVaco. That venture will see an initial investment of $US60 million into tree biotechnology. David was up until recently the Science Manager for Rubicon on the ArborGen joint venture.
David has sat on the Board of Directors of a number of companies and enterprises including GEENZ, TASMAN BIOTECHNOLOGY, TREES AND TECHNOLOGY, CAMCORE (USA), PRIMEPINE, ECOTEK, GINZENG, and AXEL.
Trevor Scott, Chairman of PEBL said that David will lead PEBL through the next phase of development. It is pleasing to report that the science programs are progressing as planned, in particular the gastric, bladder, and endometrial cancer programs are making good headway.
Trevor Scott
Chairman Pacific Edge Biotechnology
PEBL RSS